FGFR3 Antibody [G21B24] | Primary Antibodies

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000 IP1:50 IHC1:50 IF1:200

Application
WB, IP, IHC, IF

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW
125,145,165 kDa

Positive Control	Small cell lung carcinoma; Human FGFR-3 cytoplasmic fragment proteins; KMS-11 cells
Negative Control	RPMI-8226 cells

Datasheet & SDS

Biological Description

Specificity
FGFR3 Antibody [G21B24] detects endogenous levels of total FGFR3 protein.

Clone
G21B24

Synonym(s)
Fibroblast growth factor receptor 3; FGFR-3; CD333; FGFR3; JTK4

Background
Fibroblast Growth Factor Receptor 3, a member of the FGFR1-4 receptor tyrosine kinase family, is composed of three extracellular immunoglobulin-like domains, with the D2 and D3 domains binding fibroblast growth factors and heparan sulfates, a single transmembrane helix featuring a heptad motif and N-terminal GG4-like motifs that enable dimer switching, a juxtamembrane region, and a cytoplasmic tyrosine kinase domain. Upon ligand binding, FGFR3 undergoes conformational changes that promote asymmetric dimerization and autophosphorylation of key tyrosines in its kinase domain, sites analogous to those in FGFR1 important for catalytic activity and for docking of proteins such as PLCγ and Crk. FGFR3 mediates FGF signaling and regulates chondrocyte proliferation and differentiation, bone growth, and tissue homeostasis. This is achieved through transmembrane helix rotation, kinase activation, and stimulation of downstream pathways, including MAPK/ERK for cell proliferation, PI3K/AKT for survival, and PLCγ, which collectively restrain excessive cartilage growth and support angiogenesis. Gain-of-function mutations in FGFR3, such as the achondroplasia G380R mutation that stabilizes the active transmembrane dimer or mutations causing thanatophoric dysplasia, lead to skeletal dysplasias, while somatic alterations and overexpression drive oncogenesis in bladder carcinoma, multiple myeloma, and cervical cancer by promoting hyperproliferative signaling.

Background

Fibroblast Growth Factor Receptor 3, a member of the FGFR1-4 receptor tyrosine kinase family, is composed of three extracellular immunoglobulin-like domains, with the D2 and D3 domains binding fibroblast growth factors and heparan sulfates, a single transmembrane helix featuring a heptad motif and N-terminal GG4-like motifs that enable dimer switching, a juxtamembrane region, and a cytoplasmic tyrosine kinase domain. Upon ligand binding, FGFR3 undergoes conformational changes that promote asymmetric dimerization and autophosphorylation of key tyrosines in its kinase domain, sites analogous to those in FGFR1 important for catalytic activity and for docking of proteins such as PLCγ and Crk. FGFR3 mediates FGF signaling and regulates chondrocyte proliferation and differentiation, bone growth, and tissue homeostasis. This is achieved through transmembrane helix rotation, kinase activation, and stimulation of downstream pathways, including MAPK/ERK for cell proliferation, PI3K/AKT for survival, and PLCγ, which collectively restrain excessive cartilage growth and support angiogenesis. Gain-of-function mutations in FGFR3, such as the achondroplasia G380R mutation that stabilizes the active transmembrane dimer or mutations causing thanatophoric dysplasia, lead to skeletal dysplasias, while somatic alterations and overexpression drive oncogenesis in bladder carcinoma, multiple myeloma, and cervical cancer by promoting hyperproliferative signaling.

References
https://pubmed.ncbi.nlm.nih.gov/24120763/ https://pubmed.ncbi.nlm.nih.gov/21487019/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%